ArticleScientific reports2026
Modeling NRTIs and PIs class drug therapy on the dynamics of HIV infection with real patient data analysis and optimized control strategy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV/AIDS remains a major global health concern, necessitating advanced therapeutic strategies to enhance immune response and suppress viral replication. This research formulates and examines a novel fractional-order mathematical model that integrates Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Protease Inhibitors (PIs) to evaluate their collective effectiveness in managing HIV infection. Unlike existing models, our framework incorporates memory effects via fractional calculus, explicitly accounts for macrophage-derived viral load as an external reservoir, and employs optimal control theory together with bifurcation analysis to investigate long-term treatment outcomes. In addition, the model is validated using real patient data, ensuring both biological relevance and practical applicability. We determine the biologically feasible steady states of the system and compute the basic reproductive ratio ([Formula: see text]), which serves as a threshold parameter for infection persistence. Stability analysis is performed for each equilibrium point to derive conditions for disease eradication or persistence. Sensitivity analysis identifies key parameters influencing disease progression, and an optimal control strategy is derived using the Backward-Forward Runge-Kutta method to enhance CD[Formula: see text] T-cell counts while reducing infected CD[Formula: see text] cells and HIV viral load. Furthermore, the impact of drug efficacy parameters ([Formula: see text]) and ([Formula: see text]) is explored through extensive numerical simulations, demonstrating their role in mitigating viral replication and stabilizing the system. We also conduct a bifurcation analysis, including Hopf and transcritical bifurcations, to examine qualitative system dynamics. A novel Hopf bifurcation diagram illustrates the influence of fractional-order derivatives on oscillatory behavior, and a two-parameter bifurcation diagram reveals the combined effect of critical parameters on system stability. Our findings demonstrate that NRTIs and PIs effectively suppress oscillations and high infection rates, with combination therapy significantly reducing viral load and enhancing system stability. The fractional-order parameter (α) plays a crucial role in suppressing oscillations and ensuring long-term stability. Finally, a comparative study with existing literature highlights the originality and significance of our results, reinforcing the applicability of fractional-order modeling with real data in HIV/AIDS therapy research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.